NasdaqCM:BIOC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. More Details

Rewards

Loading...

Risk Analysis

Loading...

Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Biocept's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.1%

BIOC

3.5%

US Biotechs

-1.0%

US Market


1 Year Return

54.2%

BIOC

36.8%

US Biotechs

19.6%

US Market


Shareholder returns

BIOCIndustryMarket
7 Day4.1%3.5%-1.0%
30 Day1.1%4.5%2.2%
90 Day14.0%19.2%11.5%
1 Year54.2%54.2%39.0%36.8%22.3%19.6%
3 Year-97.3%-97.3%30.5%23.6%45.3%35.7%
5 Year-99.6%-99.6%43.9%33.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Biocept's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biocept undervalued compared to its fair value and its price relative to the market?

3.36x

Price to Book (PB) ratio


Share Price vs. Fair Value


Price To Earnings Ratio


Price to Earnings Growth Ratio


Price to Book Ratio


Next Steps

Future Growth

How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

66.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts


Earnings per Share Growth Forecasts


Future Return on Equity


Next Steps

Past Performance

How has Biocept performed over the past 5 years?

-10.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis


Return on Equity


Next Steps

Financial Health

How is Biocept's financial position?


Financial Position Analysis


Debt to Equity History and Analysis


Balance Sheet


Next Steps

Dividend

What is Biocept current dividend yield, its reliability and sustainability?


Dividend Yield vs Market


Stability and Growth of Payments


Current Payout to Shareholders


Future Payout to Shareholders


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Mike Nall (57 yo)

7.42yrs

Tenure

US$1,216,055

Compensation

Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, ...


CEO Compensation Analysis


Leadership Team

NamePositionTenureCompensationOwnership
Michael Nall
CEO, President & Director7.42yrsUS$1.22m0.0031%
$ 2.2k
Timothy Kennedy
CFO, Senior VP of Operations & Corporate Secretary4.5yrsUS$826.51k0.0022%
$ 1.5k
Soon Kap Hahn
24yrsno datano data
Pavel Tsinberg
Director of Technology Development3.33yrsno datano data
Michael Brown
General Counsel and Compliance & Privacy Officer3.25yrsno datano data
David Moskowitz
Vice President of Strategy & Corporate Communications4.25yrsno datano data
Michael Terry
Senior Vice President of Corporate Developmentno datano datano data
Brenda Tang
Senior Director of Marketing1yrno datano data
Gary Marchetti
Senior Director of People & Culture/Facilities1yrno datano data
Veena Singh
Senior Medical Director6.08yrsUS$115.22kno data
Michael Dugan
Senior VP0.42yrno data0.0043%
$ 3.1k

3.8yrs

Average Tenure

57yo

Average Age


Board Members

NamePositionTenureCompensationOwnership
Michael Nall
CEO, President & Director7.42yrsUS$1.22m0.0031%
$ 2.2k
M. Wilson
Interim Chair & Lead Independent Director1yrUS$82.25k0.00057%
$ 409.3
Ivor Royston
Independent Director11yrsUS$67.25k0.00043%
$ 308.8
David Hale
Director9.83yrsUS$128.50k0.0033%
$ 2.4k
Lyle Arnold
Member of Scientific Advisory Boardno dataUS$287.43k0.0022%
$ 1.6k
Samuel Riccitelli
Independent Director0.25yrno datano data
Claire Reiss
Chairwoman Emeritus9.75yrsno datano data
Marsha Chandler
Independent Director7.17yrsUS$66.00k0.00017%
$ 122.1
Fred Hirsch
Member of Clinical Advisory Boardno datano datano data
Bruce Gerhardt
Independent Director10.25yrsUS$64.75k0.0024%
$ 1.7k

8.9yrs

Average Tenure

72yo

Average Age


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume


Recent Insider Transactions

Ownership Breakdown


Top Shareholders

Company Information

Biocept, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biocept, Inc.
  • Ticker: BIOC
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$71.807m
  • Shares outstanding: 13.40m
  • Website: https://biocept.com

Number of Employees


Location

  • Biocept, Inc.
  • 9955 Mesa Rim Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOCNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2014
B002BST (Boerse-Stuttgart)YesCommon StockDEEURFeb 2014
B003DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 00:28
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.